A study in a prestigious journal places a new polyp detection system at the highest level of performance in the AI-assisted colonoscopy category
HAIFA, Israel, Feb. 22, 2024 /PRNewswire/ — MAGENTIK-OKO OOD.an Israeli technology company founded in 2014, announced today that a comprehensive study of the effectiveness of MAGENTIQ-COLO™ The CADe version is published in the prestigious Lancet Digital Health medical journal.
The study, titled “A new computer-assisted polyp detection system in screening and surveillance colonoscopy: an international multicenter, randomized, tandem trial,” was performed over a 14-month period at 10 leading medical centers, 31 endoscopists, and 952 patients examined and enrolled.
The study confirms that MAGENTIQ-COLO is at the highest level of performance in the artificial intelligence colonoscopy category. The study shows that the use of MAGENTIQ-COLO™ increased the adenoma detection rate (ADR) by 7% in absolute terms. An increased ALR is believed to be strongly associated with a reduction in colorectal cancer (CRC) incidence and patient mortality. In addition to AHR, the study also measured the impact of MAGENTIQ-COLO on adenoma miss rate (AMR) and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute terms.
“We are honored to be published by Lancet Digital Health, a journal with a phenomenal global reputation for disseminating innovative practice-changing research,” said Dror Zur, Founder and CEO, MAGENTIQ EYE. “It is important to note that measuring changes in AHR and AMR in a single study is novel. In addition to the FDA approval we received last year, this milestone is a testament to the impact of MAGENTIQ-COLO™ in improving the quality of colonoscopy and setting new standards of healthcare to save more lives.”
Link to the study
According to the US National Institutes of Health, CRC ranks as the third leading cause of cancer-related deaths. CRC usually results from the presence of polyps or other precancerous growths in the colon or rectum that can be detected during a colonoscopy, a screening and monitoring process that involves inserting an endoscope equipped with a camera at its tip through the rectum and navigating the entire length of the colon in search of abnormalities.
Although colonoscopy has become the standard of care in most developed countries, with 15 to 20 million procedures performed annually in the US alone, the high number of missed and undetected adenomas during colonoscopy procedures means that even patients who are regularly screened are still at risk of developing colon cancer. A missed polyp can lead to interval cancer, which accounts for approximately 8% to 10% of all CRCs in the US and means more than 13,500 cases of cancer that could be prevented each year with better detection.
MAGENTIQ-COLO™ is marketed in the US and Europe. For more information, please contact [email protected]
About MAGENTIQ-EYE Ltd.
Founded in 2014, MAGENTIQ-EYE offers a revolutionary AI-assisted colonoscopy solution that offers performance at the highest level known today. With global recognition from the gastroenterology community and dozens of procedures performed every day using MAGENTIQ-COLO™, we are setting the new standard in colonoscopy and saving more and more lives.
View original content to download multimedia: https://www.prnewswire.com/news-releases/lancet-digital-health-study-confirms-magentiq-colo-ai-aided-colonoscopy-technology-improves-adenoma-detection -rates -302068460.html
SOURCE MAGENTIQ-EYE LTD.
